Fluticasone furoate

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Fluticasone furoate
Fluticasone furoate.svg
Systematic (IUPAC) name
(6α,11β,16α,17α)-6,9-difluoro-17-{[(fluoro-methyl)thio]carbonyl}-11-hydroxy-16-methyl-3-oxoandrosta-1,4-dien-17-yl 2-furancarboxylate
Clinical data
AHFS/Drugs.com International Drug Names
Pregnancy cat. C for Intranasal
Legal status POM (UK) -only (US)
Routes Intranasal
Pharmacokinetic data
Bioavailability 0.51% (Intranasal)
Protein binding 91%
Metabolism Intranasal
Hepatic (CYP3A4-mediated)
Half-life 10 hours
Excretion Renal
Identifiers
CAS number 80474-14-2
ATC code R01AD12
PubChem CID 9854489
DrugBank DB00588
ChemSpider 8030195
UNII JS86977WNV YesY
ChEBI CHEBI:74899
ChEMBL CHEMBL1676
Chemical data
Formula C27H29F3O6S 
Mol. mass 538.576 g/mol

Fluticasone furoate is a synthetic corticosteroid derived from fluticasone, marketed by GlaxoSmithKline as Veramyst (US) and Avamys (Australia, Canada, EU, South Africa, Mexico, and Israel) for the treatment of allergic rhinitis. It is marketed under the name "Furamist" in India by Cipla. In India it is also marketed by Dr Reddys under the trade name 'Ennhale'. It can be administered by a nasal spray.[1]

The combination drug fluticasone furoate/vilanterol is approved for use in the United States by the Food and Drug Administration for long-term maintenance treatment of airflow obstruction in patients with COPD, including chronic bronchitis and emphysema.[2]

See also[edit]

References[edit]